Compare
Transcode Therapeutics, Inc. vs Aclaris Therapeutics, Inc. vs Aquestive Therapeutics, Inc. vs Gyre Therapeutics, Inc.
| Latest fiscal year | Transcode Therapeutics, Inc. RNAZ | Aclaris Therapeutics, Inc. ACRS | Aquestive Therapeutics, Inc. AQST | Gyre Therapeutics, Inc. GYRE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $7.83M | $44.55M | $116.59M |
| Revenue growth (YoY) | n/a | -58.2% | -22.6% | +10.2% |
| Gross margin | n/a | 73.3% (computed) | 58.3% (computed) | n/a |
| Operating margin | n/a | -975.9% | -159.5% | 9.9% |
| Net margin | n/a | -829.6% | -188.1% | 8.5% |
| Net income | -$34.66M | -$64.92M | -$83.78M | $9.88M |
| EPS (Diluted) | -$52.59 | -$0.53 | -$0.78 | $0.02 |
| Operating cash flow | -$19.52M | -$47.11M | -$52.43M | $1.01M |
| Free cash flow | -$19.52M | -$47.22M | -$52.99M | -$180.0K |
| Cash & equivalents | $17.81M | $19.96M | n/a | $37.07M |
| Total assets | $162.40M | $160.46M | $160.43M | $166.13M |
| Total liabilities | $10.52M | $57.38M | $194.09M | $23.85M |
| Shareholders' equity | $10.34M | $103.08M | -$33.66M | $106.03M |
| Return on year-end equity | -335.4% | -63.0% | n/a | 9.3% |
| Shares outstanding | 917.0K | 120.50M | 122.04M | 91.31M |
Revenue, most recent five fiscal years
| Fiscal year | Transcode Therapeutics, Inc. | Aclaris Therapeutics, Inc. | Aquestive Therapeutics, Inc. | Gyre Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $7.83M Ended 2025-12-31 | $44.55M Ended 2025-12-31 | $116.59M Ended 2025-12-31 |
| 1 year earlier | n/a | $18.72M Ended 2024-12-31 | $57.56M Ended 2024-12-31 | $105.76M Ended 2024-12-31 |
| 2 years earlier | n/a | $31.25M Ended 2023-12-31 | $50.58M Ended 2023-12-31 | $113.45M Ended 2023-12-31 |
| 3 years earlier | n/a | $29.75M Ended 2022-12-31 | $47.68M Ended 2022-12-31 | $102.29M Ended 2022-12-31 |
| 4 years earlier | n/a | $6.76M Ended 2021-12-31 | $50.83M Ended 2021-12-31 | $7.34M Ended 2021-12-31 |